• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025

    4/29/25 8:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRMD alert in real time by email

    BERKELEY HEIGHTS, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 6, 2025, and will host a corporate update conference call at 8:30am Eastern Time.

    Tuesday, May 6th @ 8:30am ET

    Domestic:1-844-676-2922
    International:1-412-634-6840
    Conference ID:10198548
    Webcast:Webcast Link
      

    About CorMedix

    CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.

    Investor Contact:

    Dan Ferry

    Managing Director

    LifeSci Advisors

    [email protected]

    (617) 430-7576



    Primary Logo

    Get the next $CRMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRMD

    DatePrice TargetRatingAnalyst
    3/7/2025$18.00Outperform
    Leerink Partners
    1/13/2025$15.00Buy
    D. Boral Capital
    8/26/2024$13.00Buy
    Rodman & Renshaw
    8/10/2023$6.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $CRMD
    SEC Filings

    See more
    • CorMedix Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - CorMedix Inc. (0001410098) (Filer)

      6/25/25 6:07:09 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CorMedix Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - CorMedix Inc. (0001410098) (Filer)

      6/23/25 7:51:56 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by CorMedix Inc.

      10-Q - CorMedix Inc. (0001410098) (Filer)

      5/6/25 8:32:06 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Commercial Officer Mistry Erin bought $14,985 worth of shares (1,500 units at $9.99), increasing direct ownership by 3% to 52,011 units (SEC Form 4)

      4 - CorMedix Inc. (0001410098) (Issuer)

      12/13/24 4:15:22 PM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Todisco Joseph bought $50,718 worth of shares (13,561 units at $3.74), increasing direct ownership by 4% to 352,839 units (SEC Form 4)

      4 - CorMedix Inc. (0001410098) (Issuer)

      3/14/24 8:45:21 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dunton Alan W bought $20,250 worth of shares (6,000 units at $3.38), increasing direct ownership by 65% to 15,250 units (SEC Form 4)

      4 - CorMedix Inc. (0001410098) (Issuer)

      12/18/23 4:47:41 PM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CorMedix inc. Announces Customer Implementation

      BERKELEY HEIGHTS, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces an update related to its Large Dialysis Organization (LDO) customer and planned implementation in the second half of 2025. CorMedix's LDO customer has commenced ordering and will begin the implementation of DefenCath in its patients. Implementation will initially target at least 50% more patients than previously communicated, with the opportunity for further expansion. In connection with this expanded utilization, CorMedix has amended its existing agr

      6/23/25 7:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference

      BERKELEY HEIGHTS, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, will be participating in the Jefferies Global Healthcare Conference, taking place in New York on June 3 - 5, 2025. Jefferies Global Healthcare ConferenceDate:Thursday, June 5, 2025Time:3:45p.m. EDTFormat:PresentationWebcast:Link About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing it

      5/30/25 8:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CorMedix Inc. to Participate in the RBC Global Healthcare Conference

      BERKELEY HEIGHTS, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, will be participating in the RBC Capital Markets Global Healthcare Conference, taking place in New York on May 20-21, 2025. RBC Capital Markets Global Healthcare ConferenceDate:Wednesday, May 21, 2025Time:3:05p.m. EDTFormat:Fireside ChatWebcast:Link   About CorMedixCorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused

      5/15/25 8:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care